Close

Mature B cell neoplasms

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Overview

Mature B-cell lymphoma is the most common type of NHL in children and adolescents, which accounts for more than 50% of all non-Hodgkin lymphoma in this group of population worldwide. Within this type, Burkitt lymphoma/leukemia and (diffuse large B-cell lymphoma) DLBCL make up the the major part. The incidence of a specific B-cell neoplasms subtype varies a lot in different regions globally. Some subtypes are more common in developed countries, while some ones are more common in underdeveloped areas, such as Burkitt's lymphoma is more endemic in African continent. Scientific reports show abundant evidence that the origination of some subtypes of B-cell lymphoma are caused by the infection of specific kinds of virus or bacteria, e.g. Epstein–Barr virus (EBV) infection plays a vital role in the pathogenesis of Burkitt's Lymphoma.

Signs, symptoms and treatments

Depending on the grade of the lymphoma, symptoms may be different. High fever, tachycardia and respiratory distress are usually shown on patients with advanced high-grade lymphoma. Shortness of breath and bone pain are organ specific symptoms. However, lymphadenopathy is the most common symptom of lymphoma, which has been reported to resolve spontaneously in some patients with low-grade lymphomas. Because of the diversity of this disease, specific therapy need to be carried out according to the subtype, such as surgery, radiation therapy, combination chemotherapy with different alkylating agents, antibiotics and antibodies.

Loading...
Products
Global Services
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.